Clinical Trial

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 7 locations 2026-05-30
Trial Details
NCT Number NCT07258407
Lead Sponsor T.O.A.D. Oncology SA
Conditions Metastatic Castration-Resistant Prostatic Cancer
Enrollment 180 participants
Start Date 2026-01-30
Primary Completion 2028-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-29